POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Clinical trial NCT05782361 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05782361
- Sponsor
- Institute of Cancer Research, United Kingdom
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-03
- Primary completion
- 2028-03-08
- Enrollment
- 19
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.